Gene of the month: BRAF

Journal of Clinical Pathology

Volumn 65, Issue 11, 2012, Pages 986-988

  Govender, Dhirendra ^a   Chetty, Runjan ^b  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; VEMURAFENIB;

APOPTOSIS; CANCER SURVIVAL; CELL SURVIVAL; COLORECTAL CANCER; DISTANT METASTASIS; EXON; GENE ACTIVATION; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENE TRANSLOCATION; HUMAN; MELANOMA; NEOPLASM; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE;

ANIMALS; CARCINOMA; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MELANOMA; NEOPLASMS; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; THYROID NEOPLASMS;

EID: 84867907842     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200960     Document Type: Review

References (40)

1. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22. (Pubitemid 29080340)
2. Bos J. Ras oncogenes in human cancer. Cancer Res 1989; 49:4682-9.
3. Davies H, Bignell G, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
4. Lahiry P, Torkmani A, Schork N, et al. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genetics 2005;11:60-74.
5. Raman M, Chen W, Cobb M. Differential regulation and properties of MAPKs. Oncogene 2007;26:3100-12. (Pubitemid 46763006)
6. Beck T, Huleihel M, Gunnell M, et al. The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res 1987;15:595-609. (Pubitemid 17233996)
7. Ghosh S, Bell R. Identification of discrete segments of human Raf-I kinase critical for high affinity binding to Ha-Ras. J Biol Chem 1994;269:30785-8. (Pubitemid 24377559)
8. Mott H, Carpenter J, Zhong S, et al. The solution structure of the Raf-1 cysteine-rich domain: a novel Ras and phospholipid binding site. Proc Natl Acad Sci USA 1996;93:8312-17. (Pubitemid 26269554)
9. Scheffler J, Waugh D, Bekesi E, et al. Characterization of a 78-residue fragment of c-Raf-1 that comprises a minimal binding domain for the interaction with Ras-GTP. J Biol Chem 1994;269:22340-6.
10. Vojtek A, Hollenberg S, Cooper J. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 1993;74:205-14. (Pubitemid 23219891)
11. Daum G, Eisenmann-Tappe I, Fries H, et al. The ins and outs of Raf kinases. Trends Biochem Sci 1994;19:474-80. (Pubitemid 24342760)
12. Morrison D, Cutler R. The complexity of RAF-1 regulation. Curr Opin Cell Biol 1997;9:174-9. (Pubitemid 27135984)
13. Marshall C. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994;4:82-9. (Pubitemid 24060300)
14. Marais R, Marshall C. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv 1996;27:101-25. (Pubitemid 26363825)
15. Moodie S, Willumsen B, Weber M, et al. Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993;260:1658-61. (Pubitemid 23247150)
16. Catling A, Schaeffer H, Reuter C, et al. A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Mol Cell Biol 1995;15:5214-25.
17. Brtva T, Drugan J, Ghosh S, et al. Two distinct RAF domains mediate interaction with RAS. J Biol Chem 1995;270:9809-12.
18. Hu C, Kariya K, Tamada M, et al. Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally modified Ha-Ras. J Biol Chem 1995;270:30274-7.
19. Marais R, Light Y, Paterson H, et al. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic Ras and tyrosine kinases. J Biol Chem 1997;272:4378-83. (Pubitemid 27078513)
20. Polsky D, Bastian B, Hazan C, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001;61:7642-6. (Pubitemid 32995060)
21. Landers J, Cassel S, George D. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 1997;57:3562-8. (Pubitemid 27355508)
22. Gelsleichter L, Gown A, Zarbo R, et al. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995;8:530-5.
23. Mercer K, Pritchard C. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochimica et Biophysica Acta 2003;1653:25-40. (Pubitemid 36627818)
24. Bonni A, Brunet A, West A, et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999;286:1358-62.
25. Storm S, Cleveland J, Rapp U. Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene 1990;5:345-51.
26. Barnier J, Papin C, Eychene A, et al. The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J Biol Chem 1995;270:23381 -9.
27. Wan P, Garnett M, Roe S, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67. (Pubitemid 38410730)
28. Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63:3955-7. (Pubitemid 36917911)
29. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7. (Pubitemid 37153748)
30. Nikiforova M, Kimura E, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404. (Pubitemid 37452745)
31. Soares P, Trovisco V, Rocha A, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 2004;444:572-6. (Pubitemid 38858382)
32. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62. (Pubitemid 40896444)
33. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients ' age but not with tumour aggressiveness. Virchows Arch 2005;446:589-95. (Pubitemid 40922263)
34. Trovisco V, Soares P, Soares R, et al. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol 2005;36:694-7. (Pubitemid 40922577)
35. Flaherty K, Puzanov I, Kim K, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
36. Houben R, Becker J, Kappel A, et al. Constitutive activation of the Ras-Raf signalling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004;3:6.
37. Jakob J, Bassett R, Ng C, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118:4014-23.
38. Long G, Menzies A, Nagrial A, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29:1239-46.
39. Karapetis C, Khambata-Ford S, Jonker D, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
40. Tol J, Nagtegaal I, Punt C. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-9.